A government-ruling party, pay attention to Syntekabio

Lee Nak-yeon, promises to Support the KRIBB

The efficacy was confirmed in animal experiments

As it is known that the drug efficacy of the new drug substance for COVID-19 being developed by Syntekabio is more than twice that of Remdesivir, a government-ruling party is paying attention to this.

 

On the 28th, Lee Nak-yeon, leader of the Democratic Party and Representative Han Jeoung-ae (General Manager of the National Disaster Recovery Committee), Seo Youngseok (Health and Medical Special Committe), Jo Seounglae, Kim Youngbae, and Han Junho visited the KRIBB in Daedeok Innopolis in Daejeon.

 

Yong Hong-taek, head of the R&D policy department of the Ministry of Science and ICT, attended.

 

On this day, the government-ruling party met with an official who took the lead in the development of COVID-19 treatment and vaccine to discuss the current status of treatment and vaccine, and to discuss a message to the public.

 

Jang Seong Kim, the KRIBB’s chairman, explained that the efficacy of Syntekabio's COVID-19 treatment candidate was twice as high as that of the standard treatment Remdesivir.

 

Syntekabio's new drug substance is known to have a therapeutic effect of 94.3% compared to 44.3% of Remdesivir as a result of animal experiments conducted through the KRIBB.

 

Lee Nak-yeon expressed interest by encouraging the researchers of the KRIBB, and at the same time confirming whether the COVID-19 candidate is twice as effective as Remdesivir in animal experiments.

 

He said, “Amid the COVID-19 crisis, we must protect the quarantine and economy and prepare for the future.

 

The KRIBB, which developed the world's fourth primate infection model, is making a feat of stabilizing the COVID-19 clinical trial.

 

We want to hear how our party can help.”, also he added, “the expansion of research facilities and data centers seemed urgent and we will help.”